FGFR1 amplification
FGFR1 amplification
|
Hormone Receptor Positive Breast Cancer
Hormone Receptor Positive Breast Cancer
|
letrozole
Resistant: B - Late Trials
|
FGFR1 amplification
FGFR1 amplification
|
Lung Non-Small Cell Squamous Cancer
Lung Non-Small Cell Squamous Cancer
|
infigratinib
Sensitive: C2 – Inclusion Criteria
|
FGFR1 amplification
FGFR1 amplification
|
Breast Cancer
Breast Cancer
|
TAS 120
Sensitive: C2 – Inclusion Criteria
|
FGFR1 amplification
FGFR1 amplification
|
Gastric Cancer
Gastric Cancer
|
ABSK-091
Sensitive: C2 – Inclusion Criteria
|
FGFR1 amplification
FGFR1 amplification
|
Bladder Cancer
Bladder Cancer
|
infigratinib
Sensitive: C2 – Inclusion Criteria
|
FGFR1 amplification
FGFR1 amplification
|
Breast Cancer
Breast Cancer
|
infigratinib
Sensitive: C2 – Inclusion Criteria
|
FGFR1 amplification
FGFR1 amplification
|
Breast Cancer
Breast Cancer
|
TKI258
Sensitive: C2 – Inclusion Criteria
|
FGFR1 amplification
FGFR1 amplification
|
Breast Cancer
Breast Cancer
|
ABSK-091
Sensitive: C2 – Inclusion Criteria
|
FGFR1 amplification
FGFR1 amplification
|
Breast Cancer
Breast Cancer
|
Aromatase inhibitor
Resistant: C3 – Early Trials
|
FGFR1 amplification
FGFR1 amplification
|
HER2 Negative Breast Cancer
HER2 Negative Breast Cancer
|
ABSK-091
Sensitive: C3 – Early Trials
|
FGFR1 amplification
FGFR1 amplification
|
Breast Cancer
Breast Cancer
|
Debio 1347
Resistant: C3 – Early Trials
|
FGFR1 amplification
FGFR1 amplification
|
Lung Non-Small Cell Squamous Cancer
Lung Non-Small Cell Squamous Cancer
|
TKI258
Sensitive: C3 – Early Trials
|
FGFR1 amplification
FGFR1 amplification
|
HER2 Negative Breast Cancer
HER2 Negative Breast Cancer
|
pazopanib
Sensitive: C4 – Case Studies
|
FGFR1 amplification
FGFR1 amplification
|
Non Small Cell Lung Cancer
NSCLC
|
M-6123
Sensitive: D – Preclinical
|
FGFR1 amplification
FGFR1 amplification
|
Estrogen Receptor Positive Breast Cancer
Estrogen Receptor Positive Breast Cancer
|
ponatinib
Sensitive: D – Preclinical
|
FGFR1 amplification
FGFR1 amplification
|
|
TAS 120
Sensitive: D – Preclinical
|
FGFR1 amplification
FGFR1 amplification
|
|
eFT226
Sensitive: D – Preclinical
|
FGFR1 amplification
FGFR1 amplification
|
Small Cell Lung Cancer
Small Cell Lung Cancer
|
TAS 120 + TAS-117
Sensitive: D – Preclinical
|
FGFR1 amplification
FGFR1 amplification
|
Non Small Cell Lung Cancer
NSCLC
|
eFT226
Sensitive: D – Preclinical
|
FGFR1 amplification
FGFR1 amplification
|
|
ponatinib
Sensitive: D – Preclinical
|
FGFR1 amplification
FGFR1 amplification
|
Lung Non-Small Cell Squamous Cancer
Lung Non-Small Cell Squamous Cancer
|
ABSK-091
Sensitive: D – Preclinical
|
FGFR1 amplification
FGFR1 amplification
|
Breast Cancer
Breast Cancer
|
afimoxifene
Resistant: D – Preclinical
|
FGFR1 amplification
FGFR1 amplification
|
Breast Cancer
Breast Cancer
|
PD 0173074
Sensitive: D – Preclinical
|
FGFR1 amplification
FGFR1 amplification
|
Gastric Cancer
Gastric Cancer
|
ponatinib
Sensitive: D – Preclinical
|
FGFR1 amplification
FGFR1 amplification
|
Breast Cancer
Breast Cancer
|
eFT226
Sensitive: D – Preclinical
|
